ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2025
Efficacy of Lacticaseibacillus rhamnosus GG in the treatment of canine atopic dermatitis: A randomized controlled study.
Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canine atopic dermatitis (CAD) is a chronic inflammatory skin disease driven by immune dysregulation. Recent studies suggest a connection between the gut microbiome and skin health, highlighting the potential for probiotics to manage dermatological conditions. Therefore, this study aimed to evaluate the effectiveness of Lacticaseibacillus rhamnosus GG in reducing skin lesion severity and pruritus in dogs with mild to moderate CAD. Forty dogs were randomly divided into two groups: one receiving L. rhamnosus GG (1 × 109 CFU/day) and the other a placebo for 90 days. All dogs maintained their standard oclacitinib therapy. Clinical outcomes were assessed using the CADESI-04 scale and a pruritus visual analogue scale (pVAS) at days 0, 45, and 90. Significant reductions in CADESI-04 scores were observed in the probiotic group compared to the placebo (p < 0.01), while pVAS scores improved only in the probiotic group. No adverse effects were reported. These findings support the potential of L. rhamnosus GG to enhance treatment outcomes in dogs with atopic dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.